Dr. Luo has been studying molecular mechanisms of human malignancies in the last 36 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 30 years, Dr. Luo has been largely focusing on the genetic and molecular mechanism of human cancers such as prostate cancer. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. He and his colleague helped to develop an ultra-low error synthetic long-read sequencing technology called LOOPSeq that can be utilized to quantify mRNA isoforms and mutation isoform distributions in single cell level. His group has discovered 21 novel fusion genes in prostate, liver and colon cancers. Subsequently, his group discovered that many of these fusion genes are recurrent in many other types of human cancers. His group also developed a genome intervention strategy targeting at the chromosomal breakpoint of fusion gene to treat cancers. Recently, his group has been focusing on machine learning prediction of prostate and liver cancers. Overall, these findings advance our understanding of how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment for human malignancies.